patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_149900 | REC_0016801 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 16.3 | 68 | female | 0 | 20 | 6.2 | 6 | entrectinib 600 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:36:01.895349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695057 | REC_0016802 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 12.5 | 63 | male | 1 | 15 | 5.3 | 3 | osimertinib 80 mg daily | 4.5 | true | MSI-H | 2026-03-15T05:36:01.895721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133971 | REC_0016803 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.3 | 63 | male | 0 | 14 | 5.8 | 2 | pembrolizumab 200 mg q3w | 31.1 | false | MSS | 2026-03-15T05:36:01.896043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491952 | REC_0016804 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 15.4 | 73 | female | 1 | 6 | 4 | 6 | alectinib 600 mg BID | 8.5 | false | MSI-H | 2026-03-15T05:36:01.896514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472492 | REC_0016805 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 14.5 | 59 | female | 1 | 6 | 3.8 | 7 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:01.896872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158064 | REC_0016806 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.6 | 67 | female | 1 | 18 | 5.8 | 6 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:01.897220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505853 | REC_0016807 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 7.9 | 56 | male | 0 | 11 | 6.7 | 7 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:36:01.897515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575656 | REC_0016808 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 4.2 | 67 | female | 1 | 22 | 7.2 | 6 | entrectinib 600 mg daily | 5.7 | true | MSS | 2026-03-15T05:36:01.897808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154280 | REC_0016809 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.1 | 75 | female | 2 | 21 | 4.5 | 4 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:01.898129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948121 | REC_0016810 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 10.8 | 62 | female | 2 | 0 | 7.6 | 5 | pembrolizumab 200 mg q3w | 7.1 | false | MSI-H | 2026-03-15T05:36:01.898641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585897 | REC_0016811 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 21 | 8.5 | 67 | female | 1 | 16 | 5.2 | 0 | pembrolizumab 200 mg q3w | 53.5 | false | MSS | 2026-03-15T05:36:01.899056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206050 | REC_0016812 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.9 | 78 | female | 3 | 9 | 6.4 | 7 | entrectinib 600 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:01.899453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999118 | REC_0016813 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.9 | 62 | female | 0 | 24 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:36:01.899840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262937 | REC_0016814 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.5 | 64 | female | 1 | 66 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.7 | true | MSS | 2026-03-15T05:36:01.900333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299701 | REC_0016815 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 8.3 | 60 | male | 0 | 11 | 7.2 | 2 | pembrolizumab 200 mg q3w | 20.5 | false | MSS | 2026-03-15T05:36:01.900751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929189 | REC_0016816 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.9 | 57 | male | 1 | 11 | 8.2 | 6 | alectinib 600 mg BID | 8.8 | true | MSS | 2026-03-15T05:36:01.901132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500498 | REC_0016817 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.8 | 66 | female | 0 | 57 | 3.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:36:01.901500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153408 | REC_0016818 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 2.1 | 74 | male | 1 | 12 | 5.8 | 1 | pembrolizumab 200 mg q3w | 20.6 | true | MSS | 2026-03-15T05:36:01.901900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948812 | REC_0016819 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 5.2 | 74 | female | 1 | 11 | 5.2 | 8 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:36:01.902293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203690 | REC_0016820 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 22.6 | 70 | female | 1 | 23 | 4.1 | 2 | sotorasib 960 mg daily | 24 | true | MSS | 2026-03-15T05:36:01.902712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422702 | REC_0016821 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8.6 | 69 | female | 1 | 16 | 5.2 | 8 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:36:01.903123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843995 | REC_0016822 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8.8 | 53 | male | 0 | 48 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.1 | true | MSS | 2026-03-15T05:36:01.903529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767303 | REC_0016823 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 19.2 | 72 | female | 1 | 18 | 3.2 | 6 | alectinib 600 mg BID | 11 | false | MSS | 2026-03-15T05:36:01.904157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421198 | REC_0016824 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9.8 | 71 | female | 1 | 23 | 6.1 | 9 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:36:01.904606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192304 | REC_0016825 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.7 | 75 | female | 1 | 14 | 3.5 | 7 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:36:01.905011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961502 | REC_0016826 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 5.7 | 68 | female | 0 | 70 | 5.8 | 1 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:36:01.905392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231798 | REC_0016827 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.6 | 55 | female | 0 | 11 | 5.4 | 7 | osimertinib 80 mg daily | 8.7 | false | MSS | 2026-03-15T05:36:01.905790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704674 | REC_0016828 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.5 | 79 | female | 1 | 10 | 5.2 | 5 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:01.906235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420788 | REC_0016829 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 9.2 | 59 | female | 1 | 6 | 4 | 1 | alectinib 600 mg BID | 9.6 | true | MSS | 2026-03-15T05:36:01.906681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623094 | REC_0016830 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.2 | 66 | male | 0 | 29 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:36:01.907095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750675 | REC_0016831 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 8.6 | 69 | male | 0 | 20 | 5.5 | 6 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:01.907493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769952 | REC_0016832 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 14.5 | 81 | male | 2 | 20 | 5 | 1 | osimertinib 80 mg daily | 27.2 | true | MSI-H | 2026-03-15T05:36:01.907905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615561 | REC_0016833 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 10.2 | 74 | female | 2 | 16 | 5.8 | 0 | osimertinib 80 mg daily | 30.5 | false | MSI-H | 2026-03-15T05:36:01.908541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932985 | REC_0016834 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 16.3 | 68 | female | 1 | 7 | 4.6 | 1 | entrectinib 600 mg daily | 19.5 | true | MSI-H | 2026-03-15T05:36:01.909034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345139 | REC_0016835 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.4 | 82 | female | 2 | 3 | 5.1 | 4 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:36:01.909518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409051 | REC_0016836 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6.3 | 64 | male | 1 | 61 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 7.6 | false | MSS | 2026-03-15T05:36:01.910176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833996 | REC_0016837 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 2.7 | 68 | female | 2 | 48 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.3 | false | MSS | 2026-03-15T05:36:01.910871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824591 | REC_0016838 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 14 | 86 | female | 2 | 15 | 5.8 | 1 | osimertinib 80 mg daily | 20 | false | MSI-H | 2026-03-15T05:36:01.911188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130086 | REC_0016839 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 7.8 | 56 | female | 0 | 16 | 4.2 | 6 | alectinib 600 mg BID | 10.7 | false | MSS | 2026-03-15T05:36:01.911499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232142 | REC_0016840 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 16.7 | 71 | male | 2 | 24 | 4.7 | 1 | entrectinib 600 mg daily | 17.8 | false | MSS | 2026-03-15T05:36:01.911882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419157 | REC_0016841 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 4 | 76 | male | 1 | 43 | 8.4 | 1 | pembrolizumab 200 mg q3w | 22.8 | false | MSS | 2026-03-15T05:36:01.912476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999282 | REC_0016842 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.2 | 63 | male | 0 | 10 | 3 | 7 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:01.912992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742442 | REC_0016843 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 37 | 7.5 | 59 | male | 1 | 12 | 4.2 | 4 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:01.913475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595069 | REC_0016844 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.7 | 69 | female | 0 | 20 | 4 | 2 | entrectinib 600 mg daily | 26 | false | MSS | 2026-03-15T05:36:01.913915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961745 | REC_0016845 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.6 | 58 | male | 1 | 9 | 3.5 | 7 | sotorasib 960 mg daily | 6.1 | true | MSS | 2026-03-15T05:36:01.914316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617750 | REC_0016846 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 5.2 | 66 | female | 1 | 11 | 5.8 | 1 | osimertinib 80 mg daily | 24.7 | false | MSS | 2026-03-15T05:36:01.914726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862907 | REC_0016847 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 13.1 | 84 | female | 2 | 19 | 6.8 | 1 | osimertinib 80 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:36:01.915072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307900 | REC_0016848 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.5 | 72 | female | 1 | 37 | 4.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:36:01.915431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146239 | REC_0016849 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.6 | 86 | female | 1 | 11 | 6.5 | 4 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:01.916139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674017 | REC_0016850 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 10.2 | 69 | female | 0 | 9 | 4.3 | 9 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:01.916846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206023 | REC_0016851 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.8 | 62 | male | 0 | 13 | 7.2 | 1 | sotorasib 960 mg daily | 27 | false | MSS | 2026-03-15T05:36:01.917541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440445 | REC_0016852 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7 | 68 | female | 1 | 22 | 6 | 8 | alectinib 600 mg BID | 4.9 | true | MSS | 2026-03-15T05:36:01.918195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306688 | REC_0016853 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 22.4 | 77 | female | 1 | 7 | 5.1 | 2 | osimertinib 80 mg daily | 21.2 | false | MSS | 2026-03-15T05:36:01.918650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922627 | REC_0016854 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 10.2 | 63 | female | 0 | 12 | 7.5 | 5 | sotorasib 960 mg daily | 9 | false | MSI-H | 2026-03-15T05:36:01.919076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269041 | REC_0016855 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.4 | 65 | female | 0 | 14 | 6.1 | 5 | osimertinib 80 mg daily | 17.7 | true | MSI-H | 2026-03-15T05:36:01.919486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214421 | REC_0016856 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.3 | 76 | male | 1 | 9 | 4.4 | 1 | sotorasib 960 mg daily | 25.9 | true | MSI-H | 2026-03-15T05:36:01.919963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602776 | REC_0016857 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9.4 | 68 | male | 1 | 18 | 5.6 | 5 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:36:01.920644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490598 | REC_0016858 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 15.2 | 59 | male | 0 | 23 | 4.3 | 0 | osimertinib 80 mg daily | 27.4 | false | MSS | 2026-03-15T05:36:01.921128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829399 | REC_0016859 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 9.7 | 73 | male | 1 | 21 | 6.4 | 2 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:01.921588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307972 | REC_0016860 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.2 | 58 | male | 1 | 7 | 4.7 | 2 | pembrolizumab 200 mg q3w | 25.6 | true | MSS | 2026-03-15T05:36:01.922001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955776 | REC_0016861 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.5 | 76 | female | 2 | 20 | 3.6 | 2 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:01.922396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769505 | REC_0016862 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 7.9 | 59 | female | 1 | 18 | 6 | 6 | sotorasib 960 mg daily | 6.4 | true | MSS | 2026-03-15T05:36:01.922998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857962 | REC_0016863 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 5.7 | 64 | female | 0 | 20 | 3.5 | 2 | pembrolizumab 200 mg q3w | 17.6 | false | MSS | 2026-03-15T05:36:01.923486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107636 | REC_0016864 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.8 | 73 | female | 2 | 23 | 6.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:36:01.923912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188235 | REC_0016865 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.9 | 63 | male | 1 | 22 | 5 | 1 | osimertinib 80 mg daily | 28.5 | false | MSS | 2026-03-15T05:36:01.924417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454176 | REC_0016866 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8 | 60 | female | 1 | 13 | 5.4 | 5 | alectinib 600 mg BID | 10.3 | false | MSS | 2026-03-15T05:36:01.925049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318496 | REC_0016867 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 7.9 | 59 | male | 0 | 10 | 4.7 | 1 | sotorasib 960 mg daily | 16 | true | MSS | 2026-03-15T05:36:01.925453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480491 | REC_0016868 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.5 | 60 | female | 0 | 13 | 7.6 | 7 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:01.925825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505482 | REC_0016869 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 13.5 | 69 | male | 0 | 7 | 6.3 | 3 | alectinib 600 mg BID | 4.6 | true | MSI-H | 2026-03-15T05:36:01.926181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337608 | REC_0016870 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.8 | 79 | female | 0 | 50 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:36:01.926527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393853 | REC_0016871 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 5.8 | 57 | female | 1 | 36 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:36:01.926895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557058 | REC_0016872 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 5.5 | 56 | female | 1 | 60 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:36:01.927251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174660 | REC_0016873 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 5.7 | 70 | female | 1 | 18 | 3.7 | 8 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:36:01.927595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560519 | REC_0016874 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.4 | 67 | male | 1 | 45 | 6.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:36:01.927922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775344 | REC_0016875 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.2 | 80 | female | 2 | 17 | 3.8 | 7 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:01.928545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672802 | REC_0016876 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11 | 80 | male | 2 | 10 | 7.2 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.928980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956396 | REC_0016877 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 7 | 60 | female | 0 | 19 | 6.2 | 6 | pembrolizumab 200 mg q3w | 7.9 | false | MSS | 2026-03-15T05:36:01.929380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744214 | REC_0016878 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.8 | 75 | female | 1 | 5 | 6.7 | 5 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:01.929788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620447 | REC_0016879 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 16 | 73 | female | 1 | 6 | 5.8 | 5 | entrectinib 600 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:36:01.930195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583994 | REC_0016880 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 10.3 | 62 | male | 1 | 31 | 4.2 | 2 | entrectinib 600 mg daily | 22.7 | false | MSI-H | 2026-03-15T05:36:01.930543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812284 | REC_0016881 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 12 | 70 | female | 1 | 22 | 5.8 | 0 | pembrolizumab 200 mg q3w | 20.7 | false | MSS | 2026-03-15T05:36:01.930855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524425 | REC_0016882 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 8 | 78 | male | 1 | 24 | 6 | 3 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:36:01.931224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350036 | REC_0016883 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 11.8 | 56 | male | 1 | 10 | 5.9 | 5 | pembrolizumab 200 mg q3w | 7 | false | MSI-H | 2026-03-15T05:36:01.931615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795779 | REC_0016884 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 6.8 | 77 | female | 1 | 18 | 6.1 | 2 | sotorasib 960 mg daily | 19.3 | true | MSS | 2026-03-15T05:36:01.931981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191000 | REC_0016885 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 7.7 | 75 | female | 3 | 14 | 6.2 | 1 | entrectinib 600 mg daily | 16 | true | MSS | 2026-03-15T05:36:01.932582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323840 | REC_0016886 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.9 | 69 | male | 1 | 11 | 6.9 | 6 | osimertinib 80 mg daily | 7 | true | MSS | 2026-03-15T05:36:01.933042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167811 | REC_0016887 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 10.7 | 62 | female | 0 | 9 | 4.1 | 1 | osimertinib 80 mg daily | 24 | true | MSS | 2026-03-15T05:36:01.933426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470350 | REC_0016888 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.3 | 67 | male | 0 | 22 | 4.7 | 1 | alectinib 600 mg BID | 15.9 | true | MSS | 2026-03-15T05:36:01.934009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887809 | REC_0016889 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 12.8 | 64 | female | 2 | 21 | 4.1 | 7 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:36:01.934412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928663 | REC_0016890 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 11.1 | 64 | male | 0 | 13 | 4.2 | 6 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:36:01.934809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178308 | REC_0016891 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.8 | 68 | female | 1 | 29 | 3.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:01.935195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979516 | REC_0016892 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 18 | 8.4 | 79 | male | 2 | 78 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 26.9 | false | MSS | 2026-03-15T05:36:01.935663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564821 | REC_0016893 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 14.7 | 72 | male | 1 | 15 | 5.9 | 2 | alectinib 600 mg BID | 20.9 | true | MSI-H | 2026-03-15T05:36:01.936187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779168 | REC_0016894 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.4 | 68 | male | 0 | 29 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:36:01.936646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618202 | REC_0016895 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.7 | 73 | male | 1 | 16 | 4.1 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:01.937102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190753 | REC_0016896 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 30 | 9.3 | 68 | female | 1 | 6 | 6.8 | 0 | entrectinib 600 mg daily | 45.8 | false | MSS | 2026-03-15T05:36:01.937467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812922 | REC_0016897 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.4 | 67 | female | 1 | 18 | 7.3 | 1 | entrectinib 600 mg daily | 11.4 | false | MSS | 2026-03-15T05:36:01.937832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330707 | REC_0016898 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.8 | 68 | female | 1 | 9 | 5 | 4 | sotorasib 960 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:36:01.938242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155018 | REC_0016899 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.6 | 58 | female | 1 | 57 | 5.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:36:01.938625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794013 | REC_0016900 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.1 | 64 | female | 1 | 21 | 7 | 1 | osimertinib 80 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:36:01.939038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.